For free samples, call 1-866-318-6977

For free samples, call 1-866-318-6977

FREQUENTLY ASKED QUESTIONS
ABOUT ACCESS AND TREATMENT

COSENTYX® CONNECT

What is COSENTYX Connect?

COSENTYX Connect is a support program designed to help offices and patients start and stay on COSENTYX.

The COSENTYX Connect Personal Support Program sets patients up for success with a number of helpful features:

Personal Support Specialist

A Personal Support Specialist from the start

Welcome Kit

Comprehensive educational resources to support their journey

$0 Co-pay card

Financial Support: $0 co-pay* program for eligible commercially insured patients. Covered Until You're Covered Program offers up to 2 years of COSENTYX for free while coverage is pursued for eligible commercially insured patients whose prescription coverage isn't initially approved

Injection Support

Supplemental injection training support

Medisafe App

Medisafe Mobile app for medication management

The COSENTYX Connect Hub helps the office and patients get coverage for and access to COSENTYX:

  • Investigate prescription coverage restrictions (eg, prior authorizations PA) and take action while working closely with your office and the insurance company to gain coverage for COSENTYX. Provide support in initiating a PA request and/or up to 2 levels of appeal. Fax communications keep your office informed every step of the way

  • Financial support: $0 co-pay* program for eligible commercially insured patients. Covered Until You're Covered Program offers up to 2 years of COSENTYX for free while coverage is pursued for eligible commercially insured patients whose prescription coverage isn't initially approved. Following Rx approval, transfer the Rx to the office's preferred or payer-mandated Specialty Pharmacy for processing and delivery. Work closely with the patient and pharmacy to ensure a timely delivery

  • Patient Support Specialist (PSS): A multilingual PSS that helps patients get started and supports them through their first year of treatment

  • Automatic enrollment into the COSENTYX Connect Personal Support Program provides patients with personalized support for up to 12 months after Rx transfer

  • A Field Reimbursement Manager (FRM) is only a phone call away to answer any Hub or reimbursement questions you may have

  • Uninsured or underinsured patients are connected to the Novartis Patient Assistance Program to determine eligibility for financial assistance

Medisafe app was developed by Medisafe Project Ltd.

*Limitations apply. Up to a $16,000 annual limit. Offer not valid under Medicare, Medicaid, or any other federal or state program. Novartis reserves the right to rescind, revoke, or amend this program without notice. Limitations may apply in MA and CA. For complete Terms & Conditions details, call 1-844-267-3689.

Certain payers have carve-outs that restrict utilization of manufacturer support program.

Covered Until You're Covered Program: Eligible patients must have commercial insurance, a valid prescription for COSENTYX, and a denial of insurance coverage based on a prior authorization request. Program requires the submission of an appeal of the coverage denial within the first 90 days of enrollment in order to remain eligible. Program provides initial 5 weekly doses (if prescribed) and monthly doses for free to patients for up to two years or until they receive insurance coverage approval, whichever occurs earlier. Program is not available to patients whose medications are reimbursed in whole or in part by Medicare, Medicaid, TRICARE, or any other federal or state program. Patients may be asked to reverify insurance coverage status during the course of the program. No purchase necessary. Program is not health insurance, nor is participation a guarantee of insurance coverage. Limitations may apply. Enrolled patients awaiting coverage for COSENTYX after two years may be eligible for a limited Program extension. Novartis Pharmaceuticals Corporation reserves the right to rescind, revoke, or amend this Program without notice.

Rx=prescription.

What is a service request form (SRF)?

A service request form (SRF) is the form that serves as an enrollment channel for the patient into the COSENTYX Connect Program via the Hub. The SRF requires pertinent information that must be filled out by both the HCP and the patient, which includes patient's prescription, patient demographics, patient insurance, requests for virtual or in-home injection demonstrations, patient signature, and prescriber signature. Without completing this form, COSENTYX Connect will not be able to assist with coverage restrictions or enroll the patient in the free COSENTYX Covered Until You're Covered* program.

If you have questions about the SRF, please contact your FRM or call 1-844-COSENTYX (1-844-267-3689).

Service request form (SRF)

*Covered Until You're Covered Program: Eligible patients must have commercial insurance, a valid prescription for COSENTYX, and a denial of insurance coverage based on a prior authorization request. Program requires the submission of an appeal of the coverage denial within the first 90 days of enrollment in order to remain eligible. Program provides initial 5 weekly doses (if prescribed) and monthly doses for free to patients for up to two years or until they receive insurance coverage approval, whichever occurs earlier. Program is not available to patients whose medications are reimbursed in whole or in part by Medicare, Medicaid, TRICARE, or any other federal or state program. Patients may be asked to reverify insurance coverage status during the course of the program. No purchase necessary. Program is not health insurance, nor is participation a guarantee of insurance coverage. Limitations may apply. Enrolled patients awaiting coverage for COSENTYX after two years may be eligible for a limited Program extension. Novartis Pharmaceuticals Corporation reserves the right to rescind, revoke, or amend this Program without notice.

What are Contracted Specialty
Pharmacies (ESPNs)?

These are Specialty Pharmacies that have contracted with Novartis to provide the following services related to COSENTYX:

  • Offer patients the COSENTYX Connect Personal Support Program, which provides access to resources and savings*†‡

  • Facilitate enrollment of eligible PA-denied patients into the Covered Until You're Covered Program* (without requirement for an SRF)

  • Inform you of the patient's status if the prescription is transferred to a payer-preferred Specialty Pharmacy

  • Connect uninsured or underinsured patients connected to the Novartis Patient Assistance Program to determine eligibility for financial assistance

Full list of Contracted Specialty
Pharmacies (ESPNs)

*Covered Until You're Covered Program: Eligible patients must have commercial insurance, a valid prescription for COSENTYX, and a denial of insurance coverage based on a prior authorization request. Program requires the submission of an appeal of the coverage denial within the first 90 days of enrollment in order to remain eligible. Program provides initial 5 weekly doses (if prescribed) and monthly doses for free to patients for up to two years or until they receive insurance coverage approval, whichever occurs earlier. Program is not available to patients whose medications are reimbursed in whole or in part by Medicare, Medicaid, TRICARE, or any other federal or state program. Patients may be asked to reverify insurance coverage status during the course of the program. No purchase necessary. Program is not health insurance, nor is participation a guarantee of insurance coverage. Limitations may apply. Enrolled patients awaiting coverage for COSENTYX after two years may be eligible for a limited Program extension. Novartis Pharmaceuticals Corporation reserves the right to rescind, revoke, or amend this Program without notice.

Limitations apply. Up to a $16,000 annual limit. Offer not valid under Medicare, Medicaid, or any other federal or state program. Novartis reserves the right to rescind, revoke, or amend this program without notice. Limitations may apply in MA and CA. For complete Terms & Conditions details, call 1-844-267-3689.

Certain payers have carve-outs that restrict utilization of manufacturer support program.

ESPN=Enhanced Specialty Pharmacy Network.

What is a Field Reimbursement Manager (FRM) and how can they help me?

Phone

An FRM is an experienced professional with strong knowledge when it comes to the COSENTYX Connect Personal Support Program, the COSENTYX Connect Hub, and navigating the reimbursement process.

FRMs can support your office by:

  • Informing customers about product access, payer requirements, forms, and documentation

  • Educating customers about COSENTYX Connect and product access process

  • Serving as a liaison between the customer and the COSENTYX Connect Hub throughout the reimbursement journey

FINANCIAL SUPPORT

How can patients sign up for $0 co-pay*?

$0 Co-pay

Eligible patients may pay nothing for their monthly COSENTYX prescriptions through the $0 Co-pay Program* if they have commercial prescription insurance. Patients may start saving today when they sign up for COSENTYX Connect. Have them visit the link below to register for $0 co-pay or call 1-844-COSENTYX (1-844-267-3689) and press option 1.

$0 co-pay sign-up

*Limitations apply. Up to a $16,000 annual limit. Offer not valid under Medicare, Medicaid, or any other federal or state program. Novartis reserves the right to rescind, revoke, or amend this program without notice. Limitations may apply in MA and CA. For complete Terms & Conditions details, call 1-844-267-3689.

Certain payers have carve-outs that restrict utilization of manufacturer support program.

Are there options for patients who are
not initially covered for COSENTYX
through their commercial or private
insurance?

Covered Until You're Covered

If patients have commercial insurance and their prescription coverage isn't initially approved, eligible* patients may get up to 2 years of COSENTYX free through Covered Until You're Covered while we work with you and your healthcare provider to try to secure coverage for COSENTYX.

Novartis offers a Patient Assistance Program (PAP) for people who have limited or no prescription coverage. If you are eligible, Novartis medications may be available for free. Visit www.PAP.Novartis.com or call 1-800-277-2254 for more information.

*Certain payers have carve-outs that restrict utilization of manufacturer support program.

Covered Until You're Covered Program: Eligible patients must have commercial insurance, a valid prescription for COSENTYX, and a denial of insurance coverage based on a prior authorization request. Program requires the submission of an appeal of the coverage denial within the first 90 days of enrollment in order to remain eligible. Program provides initial 5 weekly doses (if prescribed) and monthly doses for free to patients for up to two years or until they receive insurance coverage approval, whichever occurs earlier. Program is not available to patients whose medications are reimbursed in whole or in part by Medicare, Medicaid, TRICARE, or any other federal or state program. Patients may be asked to reverify insurance coverage status during the course of the program. No purchase necessary. Program is not health insurance, nor is participation a guarantee of insurance coverage. Limitations may apply. Enrolled patients awaiting coverage for COSENTYX after two years may be eligible for a limited Program extension. Novartis Pharmaceuticals Corporation reserves the right to rescind, revoke, or amend this Program without notice.

What is the Covered Until You're
Covered Program*?

If coverage is denied, free COSENTYX is available for up to 2 years with the Covered Until You're Covered Program* for eligible commercially insured patients while coverage is pursued.

Please fill out an SRF and fax it to the COSENTYX Connect Hub. Contact your FRM or 1-844-COSENTYX (1-844-267-3689) if you have questions.

Service request form (SRF)

*Covered Until You're Covered Program: Eligible patients must have commercial insurance, a valid prescription for COSENTYX, and a denial of insurance coverage based on a prior authorization request. Program requires the submission of an appeal of the coverage denial within the first 90 days of enrollment in order to remain eligible. Program provides initial 5 weekly doses (if prescribed) and monthly doses for free to patients for up to two years or until they receive insurance coverage approval, whichever occurs earlier. Program is not available to patients whose medications are reimbursed in whole or in part by Medicare, Medicaid, TRICARE, or any other federal or state program. Patients may be asked to reverify insurance coverage status during the course of the program. No purchase necessary. Program is not health insurance, nor is participation a guarantee of insurance coverage. Limitations may apply. Enrolled patients awaiting coverage for COSENTYX after two years may be eligible for a limited Program extension. Novartis Pharmaceuticals Corporation reserves the right to rescind, revoke, or amend this Program without notice.

Certain payers have carve-outs that restrict utilization of manufacturer support program.

INSURANCE COVERAGE

How do I appeal a prior authorization
(PA) denial?

If a prior authorization has been denied, the insurance company will provide a written explanation as to why it was denied and include information about how to request an appeal.

An appeal is a request to the patient's insurance company to reconsider their decision to deny coverage of COSENTYX. Supporting documentation such as an appeal letter, letter of medical necessity, and relevant medical record can/should be submitted.

If you have questions, please contact your FRM or call 1-844-COSENTYX (1-844-267-3689).

PA & Appeals Kits

What should I do if an insurance plan is
no longer covering COSENTYX?

Most insurance plans have a list of preferred and covered medications called a formulary. This list may be re-evaluated every year based on a number of factors, including cost, safety, and effectiveness of the medication. An insurance plan may decide to remove COSENTYX from their formulary and exclude it from coverage, which causes patients to experience a nonmedical switch to another medication. Nonmedical switching involves a change in medication in a patient who is stable on their prescribed medication for insurer cost-saving reasons, rather than for reasons related to effectiveness or safety.1

If a patient and the prescriber wish to continue on COSENTYX, follow these next steps and request a medical exception from the insurance company.

  • Call the insurance company and tell them that the patient and doctor want to stay on COSENTYX. Ask for information that can help get a medical exception so COSENTYX coverage doesn't end. A medical exception can be based on:

    • Prior medications the patient has taken for their condition

    • How long they have been on COSENTYX

    • Satisfaction with the results

    • Concerns about unnecessary doctor visits during the COVID-19 pandemic

  • Novartis is here to help: it is our goal to make the medical exception request process as seamless as possible through the COSENTYX Connect Hub or Cover My Meds

For help submitting a medical exception request, please see Formulary Change Navigation Flashcard and the Medical Exception Request Letter.

Medical Exception Request Letter

Reference: 1. Costa OS, Salam T, Duhig A, et al. Specialist physician perspectives on non-medical switching of prescription medications. J Mark Access Health Policy. 2020;8(1):1738637.

What is a medical exception?

A medical exception request is a specific type of coverage request that asks an insurance company to reconsider an adverse tiering or formulary decision with respect to an individual patient for medical reasons. It provides the insurance company the opportunity to move to an individualized, patient-centered decision-making process when their coverage policies do not meet a patient's unique needs. The prescriber must submit a statement supporting medical necessity with supporting information such as why the preferred drug would not be as effective as the requested drug for treating the condition, or/and the preferred drug would have adverse effects. Exception requests are granted when a plan determines that a requested drug is medically necessary for that patient.

Novartis is here to help: it is our goal to make the medical exception request process as seamless as possible through the COSENTYX Connect Hub or Cover My Meds

For help submitting a medical exception request, please see the Formulary Change Navigation Flashcard and the Medical Exception Request Letter.

Medical Exception Request Letter

What happens if the insurance company
denies a medical exception or PA?

If an exception request or a PA is denied, the insurance company will provide a written explanation as to why it was denied and include information about how to request an appeal. Your office may file an appeal on the patient's behalf.

Novartis is here to help: it is our goal to make the medical exception request process as seamless as possible through the COSENTYX Connect Hub or Cover My Meds

For additional information and sample letters, download the appropriate PA & Appeals Kit that corresponds to the patient's disease.

COSENTYX has a program for eligible* commercially insured patients called Covered Until You're Covered. If coverage is denied, this program provides up to 2 years of COSENTYX for free while coverage is being pursued. To enroll, submit an SRF to the COSENTYX Connect Hub.

If you have questions, please contact your FRM or call 1-844-COSENTYX (1-844-267-3689).

PA & Appeals Kits

*Certain payers have carve-outs that restrict utilization of manufacturer support program.

Covered Until You're Covered Program: Eligible patients must have commercial insurance, a valid prescription for COSENTYX, and a denial of insurance coverage based on a prior authorization request. Program requires the submission of an appeal of the coverage denial within the first 90 days of enrollment in order to remain eligible. Program provides initial 5 weekly doses (if prescribed) and monthly doses for free to patients for up to two years or until they receive insurance coverage approval, whichever occurs earlier. Program is not available to patients whose medications are reimbursed in whole or in part by Medicare, Medicaid, TRICARE, or any other federal or state program. Patients may be asked to reverify insurance coverage status during the course of the program. No purchase necessary. Program is not health insurance, nor is participation a guarantee of insurance coverage. Limitations may apply. Enrolled patients awaiting coverage for COSENTYX after two years may be eligible for a limited Program extension. Novartis Pharmaceuticals Corporation reserves the right to rescind, revoke, or amend this Program without notice.

STARTING COSENTYX

How can I provide patients with more
information about their disease?

Patients can use one of the COSENTYX patient brochures to learn more about their disease and how COSENTYX can help them take control.

Patient brochures

How can I provide patients with more
information about COSENTYX?

Patients can use one of the COSENTYX patient brochures to learn more about how COSENTYX can help them take control of their disease. For additional information about COSENTYX, patients can also visit www.cosentyx.com.

cosentyx.com

How can I find dosing information for COSENTYX?

COSENTYX Getting Started

Please review the Getting Started information for full details of dosing information and suggested prescribing approaches for each indication.

Getting Started

Are there resources that can help
patients learn how to self-inject?

Patients can either use the supplemental Quick Tips for Using the Sensoready® Pen brochure or watch helpful injection videos for step-by-step instructions on how to safely self-inject COSENTYX.

Patients enrolled in COSENTYX Connect with a Personal Support Specialist may also request a live or virtual supplemental injection training.

Injection instruction videos

Where can I learn more about the
results of COSENTYX treatment in
clinical trials?

Please visit CosentyxHCP.com to learn more about how COSENTYX performed in clinical trials.

CosentyxHCP.com

What testing do patients need to
complete before starting COSENTYX?

Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with COSENTYX. Please see the full Prescribing Information for more information about pre-treatment evaluation for tuberculosis.

Prescribing Information

INDICATIONS

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

COSENTYX® (secukinumab) is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.

WARNINGS AND PRECAUTIONS

Infections

INDICATIONS

COSENTYX® (secukinumab) is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.

COSENTYX is indicated for the treatment of adult patients with active psoriatic arthritis.

COSENTYX is indicated for the treatment of adult patients with active ankylosing spondylitis.

COSENTYX is indicated for the treatment of adult patients with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

COSENTYX is contraindicated in patients with a previous serious hypersensitivity reaction to secukinumab or to any of the excipients.

WARNINGS AND PRECAUTIONS

Infections

COSENTYX may increase the risk of infections. In clinical trials, a higher rate of infections was observed in subjects treated with COSENTYX compared to placebo-treated subjects. In placebo-controlled clinical trials in patients with moderate to severe plaque psoriasis, higher rates of common infections such as nasopharyngitis (11.4% versus 8.6%), upper respiratory tract infection (2.5% versus 0.7%), and mucocutaneous infections with candida (1.2% versus 0.3%) were observed with COSENTYX compared with placebo. A similar increase in risk of infection was seen in placebo-controlled trials in patients with psoriatic arthritis, ankylosing spondylitis and non-radiographic axial spondyloarthritis. The incidence of some types of infections appeared to be dose-dependent in clinical studies.

Exercise caution when considering the use of COSENTYX in patients with a chronic infection or a history of recurrent infection.

Instruct patients to seek medical advice if signs or symptoms suggestive of an infection occur. If a patient develops a serious infection, the patient should be closely monitored and COSENTYX should be discontinued until the infection resolves.

Pre-treatment Evaluation for Tuberculosis

Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with COSENTYX. Do not administer COSENTYX to patients with active TB infection. Initiate treatment of latent TB prior to administering COSENTYX. Consider anti-TB therapy prior to initiation of COSENTYX in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed. Patients receiving COSENTYX should be monitored closely for signs and symptoms of active TB during and after treatment.

Inflammatory Bowel Disease

Caution should be used when prescribing COSENTYX to patients with inflammatory bowel disease. Exacerbations, in some cases serious, occurred in patients treated with COSENTYX during clinical trials in plaque psoriasis, psoriatic arthritis, ankylosing spondylitis and non-radiographic axial spondyloarthritis. In addition, new onset inflammatory bowel disease cases occurred in clinical trials with COSENTYX. In an exploratory study in 59 patients with active Crohn's disease, there were trends toward greater disease activity and increased adverse events in the secukinumab group as compared to the placebo group. Patients who are treated with COSENTYX should be monitored for signs and symptoms of inflammatory bowel disease.

Hypersensitivity Reactions

Anaphylaxis and cases of urticaria occurred in patients treated with COSENTYX in clinical trials. If an anaphylactic or other serious allergic reaction occurs, administration of COSENTYX should be discontinued immediately and appropriate therapy initiated.

The removable cap of the COSENTYX Sensoready® pen and the COSENTYX prefilled syringe contains natural rubber latex which may cause an allergic reaction in latex-sensitive individuals. The safe use of the COSENTYX Sensoready pen or prefilled syringe in latex-sensitive individuals has not been studied.

Vaccinations

Prior to initiating therapy with COSENTYX, consider completion of all age appropriate immunizations according to current immunization guidelines. Patients treated with COSENTYX should not receive live vaccines.

Non-live vaccinations received during a course of COSENTYX may not elicit an immune response sufficient to prevent disease.

MOST COMMON ADVERSE REACTIONS

Most common adverse reactions (>1%) are nasopharyngitis, diarrhea, and upper respiratory tract infection.

Please see full Prescribing Information, including Medication Guide.